User profiles for Eleanor Barnes
 | Eleanor BarnesOxford University Verified email at ndm.ox.ac.uk Cited by 39020 |
[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …
was announced, containing far more mutations in Spike (S) than previously reported …
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man
E Barnes, A Folgori, S Capone, L Swadling… - Science translational …, 2012 - science.org
Currently, no vaccine exists for hepatitis C virus (HCV), a major pathogen thought to infect
170 million people globally. Many studies suggest that host T cell responses are critical for …
170 million people globally. Many studies suggest that host T cell responses are critical for …
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
A protective vaccine against hepatitis C virus (HCV) remains an unmet clinical need. HCV
infects millions of people worldwide and is a leading cause of liver cirrhosis and …
infects millions of people worldwide and is a leading cause of liver cirrhosis and …
MAIT cell activation augments adenovirus vector vaccine immunogenicity
Mucosal-associated invariant T (MAIT) cells are innate sensors of viruses and can augment
early immune responses and contribute to protection. We hypothesized that MAIT cells may …
early immune responses and contribute to protection. We hypothesized that MAIT cells may …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
…, CS Andrade, F Andritsou, R Anslow, EH Arbe-Barnes… - The Lancet, 2021 - thelancet.com
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
…, O Baatarkkhuu, E Barber, E Barnes… - The lancet …, 2019 - thelancet.com
Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual
mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV …
mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV …
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection
Background & Aims: Cellular immune responses are thought to play a key role in the
resolution of primary HCV infection. Although it has been consistently shown that CD4+ T-cell …
resolution of primary HCV infection. Although it has been consistently shown that CD4+ T-cell …
Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells
Human mucosal associated invariant T (MAIT) CD8 + and Tc17 cells are important tissue-homing
cell populations, characterized by high expression of CD161 ( ++ ) and type-17 …
cell populations, characterized by high expression of CD161 ( ++ ) and type-17 …
[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …
…, F Andritsou, R Anslow, M Appleby, EH Arbe-Barnes… - The Lancet, 2021 - thelancet.com
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[HTML][HTML] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled …
…, A Ali, E Allen, JL Allison, R Anslow, EH Arbe-Barnes… - The Lancet, 2020 - thelancet.com
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …